Back to Search Results
Image Place holder

Mian Shahzad, MD, PhD

★★★★★
★★★★★
4.8 (125 ratings)
Specialty: Gynecologic Oncology
Sub Specialty: Gynecologic Oncology
Program: Gynecologic Oncology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Cervical Cancer, Endometrial (Uterine) Cancer, Ovarian Cancer, Vaginal Cancer, Vulvar Cancer

Dr. Shahzad was recruited to Moffitt Cancer Center in 2013 as a gynecologic oncologist in The Center for Women’s Oncology. He completed his Gynecology Oncology fellowship training at the prestigious University of Wisconsin-Madison, School of Medicine and Public Health, alongside with PhD in endocrinology-reproductive physiology with special focus in cancer biology. Early in his career, he has rapidly distinguished himself as a future thought leader in the field. Prior to his clinical fellowship, he earned a Master of Science degree in Cancer Biology and Molecular Carcinogenesis at the University of Texas/MD Anderson Cancer Center and received dedicated basic science research training as a Women's Reproductive Health Research Scholar from Baylor College of Medicine and UT MD Anderson Cancer Center, Houston, Texas.  He has authored and co-authored numerous scientific publications, including peer-reviewed articles, book chapters and invited articles. Dr. Shahzad's clinical interests are in the surgical management of advanced gynecologic malignancies, including cytoreductive surgery for ovarian cancer, complex minimally invasive laparoscopic and robotic surgery for endometrial and cervical cancers as well as fertility sparing surgical techniques.  Dr. Shahzad also sees patients at Moffitt Cancer Center at International Plaza.


Education & Training

Board Certification:

  • Obstetrics & Gynecology - Gynecologic Oncology

Fellowship:

  • Baylor College of Medicine and UT MD Anderson Cancer Center - Women's Reproductive Health Research Scholar
  • University of Wisconsin Carbone Cancer Center - Gynecologic Oncology

Residency:

  • State University of New York - Obstetrics and Gynecology

Medical School:

  • Ross University School of Medicine - MD
Awards
Start Year: End Year: 2011 JG Moore Award: Best Basic Science Presentation, Sponsor: Western Association of Gynecologic Oncologists
Start Year: End Year: 2010 Deborah Gonzalez Women's Health Fellowship Award, Sponsor: The Foundation for Women's Wellness
Start Year: End Year: 2008 Ovarian Cancer Research Award, Sponsor: Society of Gynecologic Oncology
Participating Trials

CLINICAL TRIAL 20872
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)
Condition: Gynecological Tumor
Intervention: Epacadostat (); INCAGN02385 (); INCAGN02390 (); INCB024360 (Epacadostat); INCMGA00012 (); Pemigatinib ()
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Mushtaq MU, Shahzad M, Shah AY, Chaudhary SG, Zafar MU, Anwar I, Neupane K, Khalid A, Ahmed N, Bansal R, Balusu R, Singh AK, Abhyankar SH, Callander NS, Hematti P, McGuirk JP. Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. Front Immunol. 2022 Oct.13:1005031. Pubmedid: 36263054. Pmcid: PMC9574024.
  • Oswald LB, Eisel SL, Tometich DB, Bryant C, Hoogland AI, Small BJ, Apte SM, Chon HS, Shahzad MM, Gonzalez BD, Jim HSL. Cumulative burden of symptomatology in patients with gynecologic malignancies undergoing chemotherapy. Health Psychol. 2022 Nov.41(11):864-873. Pubmedid: 35901399. Pmcid: PMC9588549.
  • Martin AL, Sinha S, Peres LC, Hakam A, Chon HS, Hoffman MS, Shahzad MM, Wenham RM, Chern JY. The impact of distance to closest negative margin on survival after pelvic exenteration. Gynecol Oncol. 2022 Jun.165(3):514-521. Pubmedid: 35487774.
  • Lam C, Ha K, Hakam A, Shahzad MMK. Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism. Gynecol Oncol Rep. 2022 Jun.41:100992. Pubmedid: 35540026. Pmcid: PMC9079239.
  • Kuznicki ML, Mallen A, Ha K, McClung EC, Castaneda AV, Cao B, Fridley BL, Chon HS, Chern JY, Hoffman M, Wenham RM, Matsuo K, Shahzad MMK. Prognostic features of endometrial cancer metastasis to the central nervous system. PLoS One. 2022 Aug.17(8):e0268794. Pubmedid: 36018828. Pmcid: PMC9417007.
  • Martin A, Wells A, Anderson ML, Chern JY, Rutherford TJ, Shahzad MM, Wenham RM, Hoffman MS. Trends in ureteral surgery on an academic gynecologic oncology service. Gynecol Oncol. 2021 Dec.163(3):552-556. Pubmedid: 34674890.
  • Chang EJ, Jooya ND, Ciesielski KM, Shahzad MM, Roman LD, Matsuo K. Intraoperative tumor spill during minimally invasive hysterectomy for endometrial cancer: A survey study on experience and practice. Eur J Obstet Gynecol Reprod Biol. 2021 Dec.267:256-261. Pubmedid: 34837855.
  • Bulls HW, Hoogland AI, Small BJ, Kennedy B, James BW, Arboleda BL, Shahzad MMK, Gonzalez BD, Jim HSL. Lagged Relationships Among Chemotherapy-Induced Peripheral Neuropathy, Sleep Quality, and Physical Activity During and After Chemotherapy. Ann Behav Med. 2021 Aug.55(9):844-852. Pubmedid: 33196081. Pmcid: PMC8382147.
  • Asamoah FA, Yarney J, Scott A, Vanderpuye V, Yuan Z, Fernandez DC, Montejo ME, Agyeman M, Boateng SN, Anarfi K, Aidoo C, Shahzad MM, Chern JY, Chon HS, Wenham RM, Yamoah K, Ahmed KA. Comparison of Definitive Cervical Cancer Management With Chemotherapy and Radiation Between Two Centers With Variable Resources and Opportunities for Improved Treatment. JCO Glob Oncol. 2020 Oct.6:1510-1518. Pubmedid: 33021855. Pmcid: PMC7605379.
  • Rishi A, Rollins M, Ahmed KA, Hunt DC, Sarkar P, Fernandez DC, Hoffman MS, Apte SM, Shahzad MMK, Chon HS, Chern JY, Wenham RM, Montejo ME. High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity. Gynecol Oncol. 2020 Feb.156(2):349-356. Pubmedid: 31771865.
  • Matsuo K, Cripe JC, Kurnit KC, Kaneda M, Garneau AS, Glaser GE, Nizam A, Schillinger RM, Kuznicki ML, Yabuno A, Yanai S, Garofalo DM, Suzuki J, St Laurent JD, Yen TT, Liu AY, Shida M, Kakuda M, Oishi T, Nishio S, Marcus JZ, Adachi S, Kurokawa T, Ross MS, Horowitz MP, Johnson MS, Kim MK, Melamed A, Machado KK, Yoshihara K, Yoshida Y, Enomoto T, Ushijima K, Satoh S, Ueda Y, Mikami M, Rimel BJ, Stone RL, Growdon WB, Okamoto A, Guntupalli SR, Hasegawa K, Shahzad MMK, Im DD, Frimer M, Gostout BS, Ueland FR, Nagao S, Soliman PT, Thaker PH, Wright JD, Roman LD. Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. Gynecol Oncol. 2019 Oct.155(1):39-50. Pubmedid: 31427143. Pmcid: PMC7537353.
  • Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, Klobocista MM, Im DD, Satoh S, Baba T, Ikeda Y, Bush SH, Hasegawa K, Blake EA, Takekuma M, Shida M, Nishimura M, Adachi S, Pejovic T, Takeuchi S, Yokoyama T, Ueda Y, Iwasaki K, Miyake TM, Yanai S, Nagano T, Takano T, Shahzad MM, Ueland FR, Kelley JL, Roman LD. Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years. Surg Oncol. 2019 Jun.29:25-32. Pubmedid: 31196490. Pmcid: PMC7523232.
  • Harrison RF, Mcnamara JE, Beaumont CB, Sadowski EA, Chappell RJ, Shahzad MM, Spencer RJ, Al-Niaimi AN, Barroilhet LM, Rose SL, Kushner DM. Using simple radiologic measurements to anticipate surgical challenge in endometrial cancer: a prospective study. Int J Gynecol Cancer. 2019 Jan.29(1):102-107. Pubmedid: 30640690.
  • Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Enomoto T, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. Ann Surg Oncol. 2018 Sep.25(9):2756-2766. Pubmedid: 29971677. Pmcid: PMC7523233.
  • Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element. Surg Oncol. 2018 Sep.27(3):433-440. Pubmedid: 30217299. Pmcid: PMC7526039.
  • Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Enomoto T, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. Ann Surg Oncol. 2018 Nov.25(12):3676-3684. Pubmedid: 30105438. Pmcid: PMC7521084.
  • Matsuo K, Johnson MS, Im DD, Ross MS, Bush SH, Yunokawa M, Blake EA, Takano T, Klobocista MM, Hasegawa K, Ueda Y, Shida M, Baba T, Satoh S, Yokoyama T, Machida H, Ikeda Y, Adachi S, Miyake TM, Iwasaki K, Yanai S, Takeuchi S, Nishimura M, Nagano T, Takekuma M, Shahzad MMK, Pejovic T, Omatsu K, Kelley JL, Ueland FR, Roman LD. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. J Surg Oncol. 2018 Mar.117(3):488-496. Pubmedid: 29044542. Pmcid: PMC7521112.
  • Shahzad MMK, Felder M, Ludwig K, Van Galder HR, Anderson ML, Kim J, Cook ME, Kapur AK, Patankar MS. Trans10,cis12 conjugated linoleic acid inhibits proliferation and migration of ovarian cancer cells by inducing ER stress, autophagy, and modulation of Src. PLoS One. 2018 Jan.13(1):e0189524. Pubmedid: 29324748. Pmcid: PMC5764254.
  • Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. J Surg Oncol. 2018 Feb.117(2):236-244. Pubmedid: 28787528. Pmcid: PMC7526036.
  • Matsuo K, Ross MS, Im DD, Klobocista MM, Bush SH, Johnson MS, Takano T, Blake EA, Ikeda Y, Nishimura M, Ueda Y, Shida M, Hasegawa K, Baba T, Adachi S, Yokoyama T, Satoh S, Machida H, Yanai S, Iwasaki K, Miyake TM, Takeuchi S, Takekuma M, Nagano T, Yunokawa M, Pejovic T, Omatsu K, Shahzad MMK, Kelley JL, Ueland FR, Roman LD. Significance of venous thromboembolism in women with uterine carcinosarcoma. Gynecol Oncol. 2018 Feb.148(2):267-274. Pubmedid: 29248197. Pmcid: PMC7529359.
  • Boac BM, Xiong Y, Apte SM, Wenham RM, Shahzad MM, Munroe DG, Lancaster JM, Chon HS. Adherence to practice guidelines is associated with reduced referral times for patients with ovarian cancer. Am J Obstet Gynecol. 2018 Apr.218(4):436.e1-436.e7. Pubmedid: 29353030.
  • Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, Klobocista MM, Im DD, Satoh S, Baba T, Ikeda Y, Bush SH, Hasegawa K, Blake EA, Takekuma M, Shida M, Nishimura M, Adachi S, Pejovic T, Takeuchi S, Yokoyama T, Ueda Y, Iwasaki K, Miyake TM, Yanai S, Nagano T, Takano T, Shahzad MM, Ueland FR, Kelley JL, Roman LD. Clinical utility of CA-125 in the management of uterine carcinosarcoma. J Gynecol Oncol. 2018 11.29(6):e88. Pubmedid: 30207096. Pmcid: PMC6189428.
  • Matsuo K, Machida H, Horowitz MP, Shahzad MMK, Guntupalli SR, Roman LD, Wright JD. Risk of metachronous ovarian cancer after ovarian conservation in young women with stage I cervical cancer. Am J Obstet Gynecol. 2017 Nov.217(5):580.e1-580.e10. Pubmedid: 28666700. Pmcid: PMC7523226.
  • Kuznicki ML, Robertson SE, Hakam A, Shahzad MM. Metastatic uterine tumor resembling ovarian sex cord tumor: A case report and review of the literature. Gynecol Oncol Rep. 2017 Nov.22:64-68. Pubmedid: 29034309. Pmcid: PMC5633755.
  • Chon HS, Kang S, Lee JK, Apte SM, Shahzad MM, Williams-Elson I, Wenham RM. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers. BMC Cancer. 2017 Jun.17(1):407. Pubmedid: 28595616. Pmcid: PMC5465458.
  • Matsuo K, Ross MS, Bush SH, Yunokawa M, Blake EA, Takano T, Ueda Y, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Takeuchi S, Nishimura M, Iwasaki K, Yanai S, Klobocista MM, Johnson MS, Machida H, Hasegawa K, Miyake TM, Nagano T, Pejovic T, Shahzad MM, Im DD, Omatsu K, Ueland FR, Kelley JL, Roman LD. Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. Gynecol Oncol. 2017 Feb.144(2):329-335. Pubmedid: 27931750. Pmcid: PMC7526046.
  • Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, Klobocista MM, Im DD, Satoh S, Baba T, Ikeda Y, Bush SH, Hasegawa K, Blake EA, Takekuma M, Shida M, Nishimura M, Adachi S, Pejovic T, Takeuchi S, Yokoyama T, Ueda Y, Iwasaki K, Miyake TM, Yanai S, Nagano T, Takano T, Shahzad MMK, Ueland FR, Kelley JL, Roman LD. Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. Gynecol Oncol. 2017 Dec.147(3):565-571. Pubmedid: 29056442. Pmcid: PMC7526037.
  • Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec.21(10):2785-2795. Pubmedid: 29212026. Pmcid: PMC5749980.
  • Matsuo K, Omatsu K, Ross MS, Johnson MS, Yunokawa M, Klobocista MM, Im DD, Bush SH, Ueda Y, Takano T, Blake EA, Hasegawa K, Baba T, Shida M, Satoh S, Yokoyama T, Machida H, Adachi S, Ikeda Y, Iwasaki K, Miyake TM, Yanai S, Nishimura M, Nagano T, Takekuma M, Takeuchi S, Pejovic T, Shahzad MM, Ueland FR, Kelley JL, Roman LD. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecol Oncol. 2017 Apr.145(1):78-87. Pubmedid: 28215838. Pmcid: PMC7529360.
  • Abdallah R, Bush SH, Chon HS, Apte SM, Wenham RM, Shahzad MM. Therapeutic Dilemma: Prognostic Factors and Outcome for Neuroendocrine Tumors of the Cervix. Int J Gynecol Cancer. 2016 Mar.26(3):553-560. Pubmedid: 26825841.
  • Matsuo K, Takazawa Y, Ross MS, Elishaev E, Podzielinski I, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Matsuzaki S, Baba T, Satoh S, Shida M, Nishikawa T, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Fujiwara K, Hazama Y, Kadogami D, Moffitt MN, Takeuchi S, Nishimura M, Iwasaki K, Ushioda N, Johnson MS, Yoshida M, Hakam A, Li SW, Richmond AM, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Yamaguchi K, Oishi T, Kajiwara H, Hasegawa K, Yasuda M, Kawana K, Suda K, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Wakatsuki A, Sugiyama T, Pejovic T, Nagano T, Shimoya K, Andoh M, Shiki Y, Enomoto T, Sasaki T, Fujiwara K, Mikami M, Shimada M, Konishi I, Kimura T, Post MD, Shahzad MM, Im DD, Yoshida H, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Ann Oncol. 2016 Jul.27(7):1257-1266. Pubmedid: 27052653.
  • Ahdallah R, Morse B, Hakam A, Shahzad MM. Pelvic squamous cell carcinoma of unknown primary: a case report and review of the literature. Eur J Gynaecol Oncol. 2016 Jul.37(3):430-433. Pubmedid: 27352581.
  • Boac BM, Xiong Y, Marchion DC, Abbasi F, Bush SH, Ramirez IJ, Khulpateea BR, Clair McClung E, Berry AL, Zgheib NB, Chon HS, Shahzad MM, Judson PL, Wenham RM, Apte SM, Berglund AE, Magliocco AM, Lancaster JM. Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance. Gynecol Oncol. 2016 Feb.140(2):259-263. Pubmedid: 26731723. Pmcid: PMC4724442.
  • Al-Niaimi A, Dickson EL, Albertin C, Karnowski J, Niemi C, Spencer R, Shahzad MM, Uppal S, Saha S, Rice L, Nally AM. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma. Gynecol Oncol. 2016 Dec.143(3):521-525. Pubmedid: 27693123.
  • Schickler RL, Abdallah R, McClung EC, Shahzad MM. Primary peritoneal carcinoma presenting as a Sister Mary Joseph's nodule: A case report and review of the literature. Gynecol Oncol Rep. 2016 Aug.17:20-22. Pubmedid: 27354995. Pmcid: PMC4898916.
  • Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014 Jan.132(1):166-175. Pubmedid: 24183729. Pmcid: PMC3946949.
  • Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013 Nov.3(11):1302-1315. Pubmedid: 24002999. Pmcid: PMC3855315.
  • Shinn EH, Lenihan DJ, Urbauer DL, Basen-Engquist K, Valentine AD, Palmero LC, Woods ML, Patel P, Nick AM, Shahzad MM, Stone RL, Golden A, Atkinson E, Lutgendorf SK, Sood AK. Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev. 2013 Nov.22(11):2102-2109. Pubmedid: 24045927. Pmcid: PMC3830519.
  • Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MM, Bottsford-Miller J, Langley RR, Cole SW, Lutgendorf SK, Siddik ZH, Sood AK. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia. 2013 May.15(5):502-510. Pubmedid: 23633922. Pmcid: PMC3638353.
  • Shahzad MM, Shin YH, Matsuo K, Lu C, Nishimura M, Shen DY, Kang Y, Hu W, Mora EM, Rodriguez-Aguayo C, Kapur A, Bottsford-Miller J, Lopez-Berestein G, Rajkovic A, Sood AK. Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett. 2013 Apr.330(2):123-129. Pubmedid: 22776561. Pmcid: PMC3498611.
  • Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK. Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun. 2013.4:1403. Pubmedid: 23360994. Pmcid: PMC3561638.
  • Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012 Feb.366(7):610-618. Pubmedid: 22335738. Pmcid: PMC3296780.
  • Olawaiye AB, Godoy HE, Shahzad MM, Rauh-Hain JA, Lele SB, Odunsi K. Comparison of outcomes in patients treated with multi-agent regiments of cisplatin, adriamycin, and VP-16 versus carboplatin and paclitaxel for advanced and recurrent endometrial cancer. Eur J Gynaecol Oncol. 2012.33(5):477-479. Pubmedid: 23185791. Pmcid: PMC5100898.
  • Gold AM, Zucker NA, Shahzad MM, Kushner DM. Community screening leading to the diagnosis of androgen insensitivity syndrome at the age of 65. Gynecol Oncol Case Rep. 2012.3:23-25. Pubmedid: 24371658. Pmcid: PMC3862298.
  • Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011 Sep.71(18):6030-6039. Pubmedid: 21795478. Pmcid: PMC3174342.
  • Matsuo K, Eno ML, Ahn EH, Shahzad MM, Im DD, Rosenshein NB, Sood AK. Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer. Am J Clin Oncol. 2011 Oct.34(5):488-493. Pubmedid: 20921883. Pmcid: PMC3183315.
  • Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clin Cancer Res. 2011 Jun.17(11):3716-3726. Pubmedid: 21512144. Pmcid: PMC3108184.
  • Moreno-Smith M, Lu C, Shahzad MM, Pena GN, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, Berestein GL, Cole SW, Lutgendorf SK, Sood AK. Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res. 2011 Jun.17(11):3649-3659. Pubmedid: 21531818. Pmcid: PMC3107884.
  • Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK. Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res. 2011 Aug.17(16):5367-5378. Pubmedid: 21737505. Pmcid: PMC4028171.
  • Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res. 2011 Apr.17(7):1713-1721. Pubmedid: 21300758. Pmcid: PMC3077122.
  • Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, Thanapprapasr D, Roh JW, Gaur P, Nair MP, Park YY, Sabnis N, Deavers MT, Lee JS, Ellis LM, Lopez-Berestein G, McConathy WJ, Prokai L, Lacko AG, Sood AK. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia. 2011 Apr.13(4):309-319. Pubmedid: 21472135. Pmcid: PMC3071079.
  • Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2010 Nov.285(46):35462-35470. Pubmedid: 20826776. Pmcid: PMC2975170.
  • Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May.16(9):2562-2570. Pubmedid: 20388851. Pmcid: PMC3955167.
  • Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010 May.70(9):3687-3696. Pubmedid: 20430760. Pmcid: PMC3202607.
  • Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010 May.120(5):1515-1523. Pubmedid: 20389021. Pmcid: PMC2860925.
  • Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010 Feb.9(3):176-182. Pubmedid: 20009575. Pmcid: PMC3155813.
  • Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 2010 Aug.16(15):3910-3922. Pubmedid: 20538762. Pmcid: PMC2912984.
  • Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug.9(8):2377-2388. Pubmedid: 20682653. Pmcid: PMC2933364.
  • Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug.18(2):185-197. Pubmedid: 20708159. Pmcid: PMC2923653.
  • Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther. 2010 Apr.9(4):985-995. Pubmedid: 20371710. Pmcid: PMC2852465.
  • Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep.101(17):1193-1205. Pubmedid: 19641174. Pmcid: PMC2736292.
  • Lamkin DM, Spitz DR, Shahzad MM, Zimmerman B, Lenihan DJ, Degeest K, Lubaroff DM, Shinn EH, Sood AK, Lutgendorf SK. Glucose as a prognostic factor in ovarian carcinoma. Cancer. 2009 Mar.115(5):1021-1027. Pubmedid: 19156916. Pmcid: PMC2649990.
  • Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun.15(11):3770-3780. Pubmedid: 19470734. Pmcid: PMC2752981.
  • Shahzad MM, Lopez-Berestein G, Sood AK. Novel strategies for reversing platinum resistance. Drug Resist Updat. 2009 Dec.12(6):148-152. Pubmedid: 19805003. Pmcid: PMC2789192.
  • Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009 Aug.8(16):1596-1603. Pubmedid: 19738426. Pmcid: PMC3916970.
  • Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res. 2009 Apr.15(8):2695-2702. Pubmedid: 19351748. Pmcid: PMC2746852.
  • Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008 Sep.14(17):5437-5446. Pubmedid: 18765535. Pmcid: PMC2766914.

Patient Comments
Overall Satisfaction
4.8
★★★★★
★★★★★

125 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments